Summit Therapeutics PLC
Records under this name other than patents Summit Therapeutics PLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Summit Therapeutics PLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,975,416 | Antibacterial Compounds Formerly held In force · High confidence | In force | High confidence | |
| US 9,314,456 | Antibacterial compounds Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,763,925 | Antibacterial compounds Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,842,784 | Treatment of energy utilization disease Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,987,308 | Compounds for the Treatment of Clostridium Difficile-Associated Disease Formerly held In force · High confidence | In force | High confidence | |
| US 8,383,665 | Immunomodulatory compositions Formerly held Term ended Term ended Jul 22, 2024 · From the USPTO record | Term ended | Term ended Jul 22, 2024 | From the USPTO record |
| US 9,278,091 | Compounds for the treatment of Clostridium difficile associated disease Formerly held Lapsed on the fee record Ended Mar 8, 2024 · From the USPTO record | Lapsed on the fee record | Ended Mar 8, 2024 | From the USPTO record |
| US 8,557,859 | Immunomodulatory compositions Formerly held Term ended Term ended Jan 21, 2024 · From the USPTO record | Term ended | Term ended Jan 21, 2024 | From the USPTO record |
| US 8,518,980 | Treatment of Duchenne muscular dystrophy Formerly held Lapsed on the fee record Ended Aug 27, 2021 · From the USPTO record | Lapsed on the fee record | Ended Aug 27, 2021 | From the USPTO record |
| US 8,501,713 | Drug combinations for the treatment of duchenne muscular dystrophy Formerly held Lapsed on the fee record Ended Aug 6, 2021 · From the USPTO record | Lapsed on the fee record | Ended Aug 6, 2021 | From the USPTO record |